Probiotics are live microbes which have been shown to have beneficial effects on human health (18) . Conditions susceptible to treatment with probiotics include traveler's, antibiotic-induced, and childhood diarrhea. Recently, several controlled clinical studies have also proven a role for probiotic therapy in different states of inflammatory bowel diseases (24, 33) . A particularly interesting strain is E. coli Nissle 1917 , which was equivalent to standard mesalamine in maintaining remission of ulcerative colitis (24, 33 ; W. Kruis, P. Fric, and M. Stolte, Abstr. 102nd Annu. Meet. Am. Gastroenterol. Assoc., abstr. 127, 2001). The convincing outcome of these clinical trials using probiotic bacteria has encouraged us to further explore the mode of action of these bacteria. Several modes of probiotic action have been considered. Bacterial interference with intestinal pathogens is a well-established mode of action (2, 32) and may be mediated by bacteriocins (1, 21, 22) , specific antimicrobial substances that antagonize intestinal pathogens. However, probiotics also appear to directly affect mucosal immune function through modulation of immunoglobulin A (IgA) synthesis, mucus formation, or alterations of the proversus anti-inflammatory balance of local cytokines (17) . Recent findings raise the possibility that microbe-host cell signaling might be a mode of action by which probiotic bacteria could stabilize intestinal microecology and effectively prevent colonization by enteric pathogens (31) . Prompted by studies on defensins in colonic mucosa (7, 8) we hypothesized that probiotics may act through an induction of these endogenous antibiotics.
In addition to acting as a physical barrier, the intestinal epithelium contributes to host defense by producing antimicrobial peptides in order to limit access of enteric bacteria and other microorganisms. One important class of human antimicrobial peptides is the family of defensins. These small (3-to 5-kDa) cationic peptides are distinguished as ␣-and ␤-defensins based on the positions of their three intramolecular disulfide bridges (10) . The known human ␣-defensins include the human neutrophil peptides 1 to 4 as well as the epithelial human defensin-5 (HD-5) and HD-6. Human ␤-defensin-1 (hBD-1), -2, -3, and -4 are expressed in various epithelial cells. Defensins have a broad spectrum of antimicrobial activity against bacteria, fungi, and some enveloped viruses (9) . The mechanism is not fully understood. Human neutrophil defensin 1 to 3 perforation of the cell wall through formation of multimeric pores has been described (20, 25) . Interestingly, some beta defensins, including hBD-2, may also act as chemokines (46) . HD-5 and HD-6 are expressed primarily in Paneth cells of the small intestine (19) but are also expressed by metaplastic Paneth cells in the colon during inflammatory bowel diseases (5, 43) . Interestingly ileal involvement during Crohn's disease is associated with low HD-5 and HD-6 expression, especially in the case of the NOD2 mutation (41) . The normal colonic mucosa expresses hBD-1 (6, 39, 40) , whereas hBD-2 and hBD-3 are expressed only in case of inflammation, especially in ulcerative colitis and (at a lower level or not at all) in Crohn's disease (6, 39, 40) . The functional importance of mucosal defensins in vivo has been demonstrated by the resistance of HD-5 transgenic mice to salmonella infection on expression of the human alpha defensin HD-5 (35) and the increased susceptibility to infection of mice with a gene knockout of the protease matrilysin, leading to a block in the processing of prodefensins to defensins (45) .
To test our hypothesis that probiotics may stimulate the colonic epithelial chemical defense system, we decided to study the effect of E. coli Nissle 1917 and other probiotic strains on defensin induction in human colonic epithelial cell lines in vitro and to compare this strain with known pathogenic strains of E. coli as well as with apathogenic K-12 and with fecal isolates. The probiotic bacterium E. coli Nissle 1917 was selected because, in its long history, it has been shown to be apathogenic, to effectively colonize the gut (26) , to exhibit a semirough phenotype with a well-characterized lipopolysaccharide (LPS) (11) , and to be immunomodulatory (14, 15) , as well as immunogenic (4) .
MATERIALS AND METHODS
Culture and stimulation of epithelial cells. Caco-2 cells were obtained from the American Type Culture Collection and used from passage 15 to 25. Cell monolayers were cultured in 75-cm 2 flasks (BD Biosciences, Heidelberg, Germany) in a humidified atmosphere with 5% CO 2 . Standard media for feeding cells consisted of Dulbecco's modified essential medium, 10% fetal calf serum (FCS), and 3% nonessential amino acids supplemented with 2 mM glutamine. For stimulation experiments cells were seeded in 12-well tissue culture plates (4 cm 2 /well; BD Biosciences) and used at 70 to 80% confluence. Cells were stimulated in FCS-free medium with heat-killed bacteria for 3 to 48 h. To test if other cell lines show similar effects, we tested defensin induction in T84 as well as HT29 cells.
The mitogen-activated protein (MAP) kinase inhibitors PD 98059, SB 202190, and SP600125 as well as the NF-B inhibitor helenalin were purchased from Calbiochem (Darmstadt, Germany) and resuspended in dimethyl sulfoxide. The inhibitors were added directly to the culture medium at a final concentration of 20 M 1 h prior to stimulation.
Preparation of bacteria. E. coli K-12 HB101, uropathogenic E. coli (UPEC) W536, and enteropathogenic E. coli (EPEC) were kindly supplied by J. Hacker and G. Blum-Oehler (Institute of Molecular Biology of Infection, Würzburg, Germany). E. coli Nissle 1917 (DSM 6601) and all E. coli strains as well as Lactobacillus fermentum, Lactobacillus gasseri, and three different forms of Lactobacillus acidophilus were provided by Ardeypharm (Herdecke, Germany). Lactobacillus paracasei, Lactobacillus plantarum, Pediococcus pentosaceus, and Leuconostoc mesenteroides, as well as a cocktail containing strains of all four species together, were delivered by Medipharm (Kågeröd, Sweden). An overview of serotypes, origins, and references of selected strains used is given in Tables 1 and  2 . All E. coli strains were grown overnight in Trypticase soy broth (TSB) medium at 37°C under permanent shaking. To keep bacteria in a linear growth phase, 200 l of bacterial suspension was again diluted in 5 ml of fresh TSB medium and bacteria were grown under shaking conditions at 37°C. Lactobacilli were cultured in 10 ml of De Man-Rogosa-Sharpe broth (MRS) under anaerobic conditions at 37°C overnight. As for E. coli strains, 500 l of the bacterial suspension was then diluted in MRS broth to a final volume of 10 ml and grown again at 37°C under anaerobic conditions. After 5 h lactobacilli and E. coli strains were heat killed in a water bath at 65°C for 60 min and then diluted to the appropriate concentration in FCS-free cell culture medium. For testing of dose dependence, bacteria were used at a concentration between 10 7 and 10 9 bacteria per ml. the stimulation experiments. To maintain stable conditions for all other experiments, we used heat-inactivated bacteria at a concentration of 3 ϫ 10 8 cells/ml. Testing of E. coli LPS. To look for strain-specific mechanisms of hBD-2 induction, we tested highly purified LPS generated from E. coli Nissle 1917 , which was kindly provided by U. Zähringer (Research Center Borstel, Borstel, Germany). As a control we used purified LPS from E. coli serotype O111:B4 (Sigma-Aldrich). The LPS from the control strain and E. coli Nissle 1917 LPS were diluted in FCS-free medium in different concentrations (0.1, 0.5, 1, and 5 g/ml), and the stimulation was performed for 6 h in Caco-2 cells.
RNA isolation and cDNA synthesis. After stimulation cells were washed twice with phosphate-buffered saline (PBS) and harvested with TRIzol reagent (Invitrogen, San Diego, Calif.) according to the supplier's protocol. RNA quality and quantity were determined by gel electrophoresis and photometry. Subsequently 1 g of total RNA was reverse transcribed in cDNA with oligo(dT) primers and 200 U of Superscript II (Invitrogen) according to routine procedure.
Real-time RT-PCR. Real-time reverse transcription-PCR (RT-PCR) analyses were performed in a fluorescence temperature cycler (LightCycler; Roche Diagnostics GMBH, Mannheim, Germany) as described previously (12, 40) . This technique continuously monitors the cycle-by-cycle accumulation of fluorescently labeled PCR product. Briefly, cDNA corresponding to 20 ng of RNA served as a template in a 20-l reaction mixture containing 4 mM MgCl 2 , 0.5 M (each) primer, and 1ϫ LightCycler-FastStart DNA Master SYBR Green I mix (Roche Diagnostics GMBH). Samples were loaded into capillary tubes and incubated in the fluorescence thermocycler (LightCycler). Initial denaturation at 95°C for 10 min was followed by 45 cycles, each cycle consisting of 95°C for 15 s, touchdown of Ϫ1°C/cycle from the primer-specific starting to ending annealing temperatures for 5 s, and 72°C for 10 s. For hBD-1 (sense, 5Ј ATACTTCAAAAGCAATTT TCCTTTAT 3; antisense, 5Ј TTGTCTGAGATGGCCTCAGGTGGTAAC 3Ј) and hBD-2 (sense, 5Ј CCCTTTCTGAATCCGC 3Ј; antisense, 5Ј GAGGGTCT TGTATCTCCT 3Ј) a touchdown protocol with a primary temperature of 62°C and a target temperature of 58°C was used. For HD-5 (sense, 5Ј GCCATCCT TGCTGCCATTC 3Ј; antisense, 5Ј AGATTTCACACACCCCGGAGA 3Ј), HD-6 (sense, 5Ј CCTCACCATCCTCACTGCTGTTC 3Ј; antisense, 5Ј CCATG ACAGTGCAGGTCCCATA 3Ј), and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) (sense, 5Ј CCAGCCGAGCCACATCGCTC 3Ј; antisense, 5Ј AT GAGCCCCAGCCTTCTCCAT 3Ј) we used a protocol with a primary temperature of 66°C and a target temperature of 60°C. (At the end of each run melting curve profiles were produced by cooling the sample to 65°C for 15 s and then heating slowly at 0.20°C/s to 95°C with continuous measurement of fluorescence to confirm amplification of specific transcripts.) Cycle-to-cycle fluorescence emission readings were monitored and analyzed with LightCycler software (Roche Diagnostics GMBH). The specificity of the amplification products was further verified by subjecting the amplification products to electrophoresis on a 2% agarose gel. The fragments were visualized by ethidium bromide staining, and the specificity of PCR products was verified by sequencing representative samples. Standard curves were obtained for each primer set with serial dilutions of cDNA.
All quantifications were normalized to the housekeeping GAPDH gene, which showed a very stable expression in Caco-2 cells. Relative expression is given as a ratio between target gene expression and GAPDH gene expression.
Purification and identification of hBD-2 from Caco-2 culture supernatants. Supernatants of approximately 2 ϫ 10 7 Caco-2 colon epithelial cells treated for 24 h with 3 ϫ 10 8 cells of heat-inactivated E. coli Nissle 1917/ml were applied to a heparin affinity column (1 ml; HiTrap; Pharmacia). Bound material was then eluted with 10 ml of 2 M NaCl at a flow rate of 1 ml/min. Eluted material was diafiltered against 0.1% trifluroacetic acid (TFA), pH 3, and applied to a C 2 /C 18 micro-reversed-phase high-performance liquid chromatography (HPLC) column (RPC C 2 /C 18 , SC 2.1/10, Smart-Micro-HPLC apparatus; Amersham Biosciences, Uppsala, Sweden) that was previously equilibrated with 0.1% (vol/vol) TFA in HPLC grade water. Proteins were eluted with a gradient of increasing concentrations of acetonitrile containing 0.1% (vol/vol) TFA (flow rate: 100 l/min). Fractions were then analyzed for the presence of hBD-2 by enzymelinked immunosorbent assay (ELISA) or Western blotting.
For ELISA with HPLC fractions, 96-well immunoplates (MaxiSorp; Nunc, Roskilde, Denmark) were coated at 37°C for 1 h with 10 l of each HPLC fraction and serial dilutions of natural skin-derived hBD-2 in 100 l of 0.1 M sodium bicarbonate buffer, pH 10.6. Wells were washed with PBS-0.05% Tween and blocked with 1% bovine serum albumin in PBS for 1 h at room temperature. Plates were washed twice with PBS-0.05% Tween, and wells were incubated with 100 l of hBD-2 rabbit antiserum (Peptide Institute, Osaka, Japan) diluted 1:40,000 in PBS for 1 h at room temperature. After three washes with PBS-0.05% Tween, 100 l of a 1:20,000 dilution of goat anti-rabbit IgG horseradish peroxidase (HRP) conjugate (Dianova, Hamburg, Germany) per well was incubated for 1 h at room temperature. Plates were washed again three times with PBS-0.05% Tween and filled with 100 l of peroxidase substrate (o-phenylenediamine dihydrochloride, 0.01 M in 0.1 M citrate-phosphate buffer, pH 5.0, containing 0.001% [vol/vol] H 2 O 2 )/well. The enzymatic reaction was stopped with 2 M sulfuric acid, and absorbance at 492 nm was determined in a multichannel photometer (Sunrise; Tecan, Crailsheim, Germany). The ELISA was sensitive to 0.3 ng of hBD-2/well.
For Western blot analysis C 2 /C 18 fractions eluting like natural hBD-2 at 43 to 47% acetonitrile were pooled and loaded onto a sodium dodecyl sulfate-16.5% Tricine polyacrylamide gel containing 8 M urea (36) . Proteins were transferred to a Protran-nitrocellulose membrane (Schleicher & Schuell BioScience, Dassel, Germany), blocked for 1 h in blocking buffer (5% [wt/vol] nonfat powdered milk in PBS-0.05% Tween), and then incubated for 18 h at 4°C in 3% (wt/vol) nonfat powdered milk in PBS-0.05% Tween containing 1:40,000-diluted hBD-2 rabbit antiserum (Peptide Institute). The membrane was washed with PBS-0.05% Tween six times for 5 min each, and then incubated for 1 h in 3% (wt/vol) nonfat powdered milk in PBS-0.05% Tween containing a 1:200,000 dilution of goat anti-rabbit IgG HRP conjugate (Dianova). After six washes as described above, the membrane was incubated for 5 min with chemiluminescent peroxidase substrate (Sigma, Taufkirchen, Germany) and visualized with a Diana III cooled charge-coupled device camera imaging system (Raytest, Straubenhardt, Germany). Densitometric quantifications were done with AIDA evaluation software (Raytest).
hBD-2 reporter plasmid construction. To analyze hBD-2 promoter activity, 2,338 bp of the human hBD-2 promoter was amplified with the primers 5Ј CAG TAC AGC AGC AGT GAT AG 3Ј and 5Ј GGG GAG GAC ATC AAG CCT T 3Ј. The amplification product was subcloned into the promoterless pGL3-basic firefly luciferase vector (Promega, Madison, Wis.) to generate reporter plasmid hBD-2-2338-luc.
The functional role of putative binding sites for the transcription factor NF-B as well as for the transcription factor AP-1 in the hBD-2 promoter region was studied by site-directed mutagenesis. The QuikChange XL site-directed mutagenesis kit (Stratagene, La Jolla, Calif.) was used as indicated by the supplier for the introduction of mutations in the hBD-2-2338-luc plasmid. The two putative NF-B binding sites at positions Ϫ205 to Ϫ186 and Ϫ596 to Ϫ572 were mutated with the mutant NF-B primers to introduce NF-B mutations as described by Tsutsumi-Ishii and Nagaoka (37) . For the first position (HBD2-NF-B-mut1, positions Ϫ205 to Ϫ186) we used the following primers: sense, 5Ј CTGGTCCCAAGAGCAGGAGGAAGACGCGTTCTGGTACCTCCTGAGT The putative AP-1 binding site at position Ϫ127 to Ϫ121 was mutated with mutant AP-1 primers (sense, 5Ј CATTGTTCTTTGAGGACCATTCTCAGGC TCACCAGGTAAGTGGCTGAAT 3Ј; antisense, 5Ј ATTCAGCCACTTACCT GGTGAGCCTGAGAATGGTCCTCAAAGAACAATG 3Ј). The resulting hBD-2-pGL3 plasmids containing mutated NF-B and AP-1 binding sites were termed NF-B-mut1-luc (containing one mutated NF-B binding site at positions Ϫ205 to Ϫ186; see Fig. 6A ), NF-B-mut2-luc (containing one mutated NF-B binding site at position Ϫ596 to Ϫ572; see Fig. 6A ), NF-B-mut1ϩ2-luc (containing two mutated NF-B binding sites; see Fig. 6A ), AP1-mut-luc (containing a mutated AP-1 binding site; see Fig. 6A ), and AP-1ϩNF-B-mut-luc (containing two mutated NF-B binding sites and a mutated AP-1 binding site; see Fig. 6A ).
Transfection and determination of promoter activity. For hBD-2 promoter studies Caco-2 cells were seeded in 12-well plates (BD Biosciences) and used for transfection at 60 to 80% confluence. Cells were transfected with 0.5 g of the indicated hBD-2 reporter plasmids and 0.025 g of an internal-control Renilla luciferase expression plasmid (phRG-TK; Promega) by using 1 l of transfection reagent Fugene 6 (Roche Diagnostics GMBH) according to the manufacturer's instructions. Twenty-four hours after transfection cells were stimulated with bacteria for 5 h in FCS-free medium. After stimulation cells were harvested with 500 l of passive lysis buffer (Promega), and firefly luciferase activity from the hBD-2-pGL3 reporter vector and Renilla luciferase activity were measured by the Dual Luciferase assay system (Promega) on a TD-20/20 luminometer (Turner Design). Promoter activity was reported as the ratio between firefly and Renilla luciferase activities in each sample.
hBD-2 ELISA. To directly test the presence of the hBD-2 peptide in the supernatants of Caco-2 cells, a sensitive hBD-2 ELISA was established. Ninetysix-well immunoplates (MaxiSorp; Nunc) were coated at 4°C for 20 h with 50 l of hBD-2 rabbit antiserum (Peptide Institute) diluted 1:5,000 in 0.05 M carbonate buffer, pH 9.6. Subsequently, wells were blocked with 200 l of 1% bovine serum albumin in PBS for 10 min at room temperature. After three washes with 200 l of PBS-0.1% Tween 20, 100 l of cell culture supernatants per well and serial dilutions of natural skin-derived hBD-2 in cell culture medium were incubated for 30 min at room temperature. Plates were washed thrice with PBS-0.1% Tween 20, and wells were incubated for 30 min at room temperature with 50 l of biotinylated goat anti-hBD-2 antibody (Cell Concepts, Umkirch, Germany) diluted 1:2,500 to 0.2 g/ml in PBS-0.1% Tween 20. Plates were washed again three times with PBS-0.1% Tween and filled with 50 l of streptavidin-peroxidase (Roche Diagnostics; 1:10,000 in PBS-0.1% Tween 20)/well. The plates were then incubated for 30 min at room temperature, washed three times as described above, and incubated with 2,2Ј-azinobis-3-ethylbenzthiazoline-6-sulfonic acid (ABTS; Roche Diagnostics) as the development agent for 15 min at room temperature in the dark. Absorbance was measured at 405 nm with a multichannel photometer (Sunrise; Tecan).
Statistics. Experiments were performed in triplicate samples. Differences between stimulated and control cells were analyzed by two-tailed, nonpaired t test, with a P value Ͻ0.05 indicative of statistical significance.
RESULTS

E. coli Nissle 1917 and other probiotic bacteria are potent activators of hBD-2 gene expression in colonic epithelial cells.
To analyze the influence of various probiotic as well as nonprobiotic E. coli strains on defensin expression in colon epithelial cells, we treated Caco-2 cells with E. coli Nissle 1917, 9 other probiotic bacterial strains including lactobacilli, and over 40 other nonprobiotic heat-inactivated E. coli strains and analyzed ␣-and ␤-defensin gene expression by the use of realtime PCR.
Basal constitutive gene expression of hBD-1 was not affected by E. coli Nissle 1917, either over time (Fig. 1A) or with increasing dose (Fig. 2) . Similar results were obtained for the ␣-defensin HD-6, which was also not influenced by heat-inactivated E. coli Nissle 1917 at any time or any dose ( Fig. 1 and  2 ). HD-5 could be detected only at a very minimal level and inconsistently.
In contrast to that of the hBD-1, HD-5, and HD-6 genes, expression of the hBD-2 gene in Caco-2 cells was clearly induced upon treatment of the cells with E. coli Nissle 1917 and other probiotic bacteria. hBD-2 induction peaked between 3 and 6 h, but expression returned to basal values after 12 h (Fig.  1A) . E. coli K-12 and EPEC did not influence any tested defensin expression at any time (Fig. 1B) . UPEC showed its maximum induction at the same time as E. coli Nissle 1917 (data not shown). The induction of hBD-2 by E. coli Nissle 1917 was found to be dose dependent, with a maximum of 362-fold at the highest bacterial concentration tested (Fig. 2) . HB101 ) and the EPEC strain, failed to induce hBD-2 (Fig. 3A) . In addition, the 13 fecal isolates showed no significant difference in basal expression of hBD-2, with a range of 0.7-to 4-fold induction (Fig. 3A) . Further, 30 E. coli strains (not classified, as shown in Table 1 ) isolated from human feces had a range of 0.7-to 4-fold (mean, 1.5-fold) induction of hBD-2 expression (data not shown). All tested E. coli strains, including the 11 serotyped strains isolated from the feces of healthy volunteers (Table 1) specific semirough LPS phenotype, which has been described for E. coli Nissle 1917 (11), does not explain the described differences. Nissle 1917 induces the release of the hBD-2 peptide from Caco-2 cells, we analyzed supernatants of untreated as well as E. coli Nissle 1917-or E. coli K-12-treated Caco-2 cells for the presence of the hBD-2 peptide. hBD-2 peptide released in the culture supernatants was bound to a heparin affinity column. Heparin-bound material was further purified by C 2 /C 18 reversed-phase HPLC, and the resulting fractions were analyzed by ELISA and Western blotting for the presence of the hBD-2 peptide. Western blot analysis (Fig. 4A) and ELISA (not shown) detected approximately 0.5 to 1 ng of peptide in the culture supernatants of approximately 10 7 Caco-2 cells stimulated with E. coli Nissle 1917. In the supernatants of untreated cells and K-12-treated cells no hBD-2 peptide could be detected (Fig. 4A) . Furthermore, we used an hBD-2 ELISA to directly analyze supernatants of cultured Caco-2 cells treated with various strains of E. coli as well as L. fermentum. As shown in Fig. 4B , only treatment with E. coli Nissle 1917 and, to a lesser extent, L. fermentum and UPEC led to a high release of hBD-2 in the culture supernatants of Caco-2 cells.
Caco-2 cells release hBD-2 upon contact with E. coli Nissle 1917. To investigate whether E. coli
Activation of the hBD-2 promoter in Caco-2 cells by E. coli Nissle 1917. To test whether hBD-2 gene induction measured by real-time PCR correlates with hBD-2 promoter activation, the hBD-2 promoter was ligated to the firefly luciferase gene and this construct was used to transiently transfect Caco-2 cells. As a result we found that E. coli Nissle 1917 induced the hBD-2 promoter approximately sevenfold compared to promoter levels in nonstimulated Caco-2 cells (Fig. 5) . The activation of the hBD-2 promoter by the uropathogenic strain was less pronounced and coincided with the weaker induction of hBD-2 mRNA expression by this UPEC (Fig. 3) . Two randomly selected strains (serotypes O4:H-and O2:H4-; Table 1 ) from patients with inflammatory bowel disease were also tested, but none activated the hBD-2 promoter ( Fig. 5 ; only one representative strain is shown).
NF-B and AP-1 binding sites in the hBD-2 promoter are required for hBD-2 induction by E. coli Nissle 1917. To elucidate the role of putative binding sites for the transcription factors NF-B and AP-1 in the hBD-2 promoter region, we generated hBD-2 promoter luciferase expression constructs containing mutations of the two NF-B sites (positions Ϫ205 to Ϫ186 and Ϫ596 to Ϫ572) and the AP-1 site (positions Ϫ127 to Ϫ121; Fig. 6A ). Caco-2 cells transfected with these constructs were treated with E. coli Nissle 1917 and analyzed for hBD-2 promoter activation. Mutation of the two NF-B sites together with the AP-1 site abolished E. coli Nissle 1917-mediated hBD-2 promoter activation (Fig. 6B) . The same result 8 cells of heat-inactivated E. coli/ml were purified by C 2 /C 18 reversed-phase HPLC. Fractions eluting like natural hBD-2 at 43 to 47% acetonitrile were pooled and subjected to Western blot analysis using antibodies directed against hBD-2. The amounts of hBD-2 were calculated by densitometry using the indicated amounts of natural skin-derived hBD-2 as standards. was obtained by mutating only both NF-B sites (Fig. 6B) . Mutation of the proximal NF-B site (positions Ϫ205 to Ϫ186) strongly inhibited E. coli Nissle 1917-mediated activation of the hBD-2 promoter (from 8.9-fold to 1.7-fold). In contrast, mutation of the NF-B site at positions Ϫ596 to Ϫ572 did not inhibit hBD-2 promoter activation (Fig. 6B) . Mutating the AP-1 site reduced E. coli Nissle 1917-mediated hBD-2 promoter activation from 8.9-fold to 3.6-fold (Fig. 6B) . (Fig. 7) . SB 202190, a specific p38 MAP kinase inhibitor, and PD 98059, a selective inhibitor of ERK1/2, did not block E. coli Nissle 1917-mediated hBD-2 gene induction (Fig. 7) . Furthermore hBD-2 gene induction by E. coli Nissle 1917 was also blocked by treatment of the Caco-2 cells with the NF-B inhibitor helenalin (Fig. 7) . In all experiments no changes of cell morphology upon inhibitor treatment were observed, indicating that the inhibitors exhibited no cytotoxic activity.
DISCUSSION
Our results demonstrate that active as well as heat-inactivated E. coli Nissle 1917 and several other probiotic bacteria, in contrast to most nonprobiotic E. coli strains, potently induce the antimicrobial peptide hBD-2 in intestinal epithelial cells. The induction of hBD-2 by E. coli Nissle 1917 seems to be a characteristic of this and other probiotic strains, because other E. coli strains (with the exception of UPEC), including several fecal isolates (40 different strains total), failed to induce hBD-2 in Caco-2 cells. The fact that other probiotic bacteria, including several lactobacilli, also induce hBD-2 suggests that the induction of antimicrobial peptides such as hBD-2 may be a common feature of probiotics which enables these bacteria to strengthen barrier function. The induction of hBD-2 through UPEC and Nissle 1917 gives rise to the hypothesis that these bacteria contain similar (or the same?) unique molecular patterns that are responsible for hBD-2 induction and that are not present in other E. coli strains that do not induce hBD-2. But, in contrast to Nissle 1917, UPEC expresses various virulence factors, and many of them are encoded by the pathogenicity islands present in all UPEC strains (2a). It is possible that these virulence factors, which are not expressed by E. coli Nissle 1917 , are responsible for the inflammation associated with the pathogenic effects of UPEC. In contrast to hBD-2, hBD-1 remained unaffected by the bacterial strains tested. This is consistent with previous reports demonstrating constitutive hBD-1 gene expression in colon epithelial cells that was not upregulated upon treat- It is obvious that some pathogenic strains may suppress defensin release, probably as a self-defense (16, 34) , whereas other bacteria, probably including the probiotic E. coli Nissle 1917 , are protective to the host organism by inducing defensins. The protective effect documented in several controlled trials (24, 33) may be closely linked to this feature, since in the remission state defensin expression is low (6, 39, 40) and induction may prevent a bacterially induced relapse. Further evidence is given by coculture experiments, where invasion of epithelial cells by enteroinvasive pathogens is greatly reduced in the presence of E. coli Nissle 1917 (3) . It remains to be determined whether reduced pathogen growth is caused by increased beta-defensin levels induced by E. coli Nissle 1917 .
The present findings of an induction of the innate chemical defense system through E. coli Nissle 1917 may explain various experimental and clinical findings, including the initial hypothesis by the pioneer Alfred Nissle postulating that the presence of E. coli Nissle 1917 recovered from the feces of a soldier immune to salmonellosis prevented this disease (28) . Others (26) reported that the load of pathogens recovered from stool samples of newborn infants was reduced when the neonates had been colonized with E. coli Nissle 1917 . Experiments with BALB/c mice showed that oral administration of E. coli Nissle 1917 prior to infection with Candida albicans minimized the systemic spread of the pathogen (15) . The same effect was observed in Listeria monocytogenes infection experiments (15) , as well as in gnotobiotic rats when the Nissle 1917 strain was administered orally prior to a challenge with infective doses of Candida albicans (27) . These observations in animal models may well be due to induction of antimicrobial peptides, but more in vivo experiments are required to support this hypothesis.
In conclusion, our data provide the first evidence that the probiotic bacterium E. coli Nissle 1917 and other probiotic strains may exert their beneficial effects through stimulation of the synthesis of endogenous epithelial antimicrobial peptides such as hBD-2.
